Every DEF 14A that Lunai Bioworks Inc. (RENB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow RENB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RENB filings page.
Lunai Bioworks, Inc. filed definitive additional proxy soliciting materials incorporating a Form 8-K that reports the closing of its acquisition of Neurobridge IP Holdings Incorporated and issuance of Series B Convertible Preferred Stock. The materials state the Special Meeting is rescheduled for May 8, 2026 and recommend voting FOR the proposals, including the Reverse Split Proposal.
The filing incorporates disclosures about Nasdaq listing-rule compliance, the Company’s Section 5.11 stockholder solicitation covenant, and conversion mechanics for the Series B Preferred Stock; proxies already submitted remain effective.
Lunai Bioworks, Inc. is asking stockholders to approve a reverse stock split of its common stock at a ratio between 1-for-3 and 1-for-30, with the exact ratio to be chosen later by the board. The main goal is to lift the share price to help maintain the company’s Nasdaq listing after receiving a delisting determination for failing the minimum bid price rule. The split would reduce outstanding shares but leave the 350 million authorized shares unchanged, increasing the pool of unissued shares. Fractional shares would be rounded up to the next whole share, and the split is intended to be tax-free for U.S. holders. Stockholders are also being asked to approve a proposal allowing adjournment of the special meeting to solicit additional proxies if needed.
Lunai Bioworks, Inc. will hold its 2025 Annual Meeting on October 31, 2025, at 10:00 a.m. ET via live webcast. Stockholders of record on October 3, 2025 may vote on four proposals: elect four directors, a non-binding say‑on‑pay, ratify Sadler, Gibb & Associates LLC as auditor for fiscal 2026, and approve amendments to the 2023 Equity Incentive Plan.
The plan amendments would increase authorized shares to 3,476,722 (an increase of 3,042,655), add an evergreen that adjusts annually so available awards equal 15% of outstanding shares (subject to limits), add equitable adjustments, require dividends on unvested awards to accrue until vesting, prohibit option/SAR repricing without stockholder approval, clarify share counting rules, and specify change‑in‑control treatment. The Board recommends voting FOR all proposals.
There were 23,178,153 shares of common stock outstanding as of the record date. The company effected a 1‑for‑10 reverse split on September 30, 2025, and plan share figures reflect this adjustment.